Who is Stephen W. Sanger and why was he appointed to the Board?

The 8-K filing itself does not provide details on Stephen W. Sanger's background or the specific reasons for his appointment. However, the accompanying press release, incorporated by reference as Exhibit 99, should contain this information. Investors are advised to review the press release for details on his qualifications and the Board's rationale for his election.

What is the significance of adding a new director to Pfizer's Board?

Adding a new director can be significant as it may bring new expertise, perspectives, or strategic insights to the company's leadership. It can also indicate shifts in corporate governance or a response to evolving business needs. Investors should monitor the company's subsequent communications and actions for potential impacts stemming from this appointment.

When does this board change officially take effect?

The election of Stephen W. Sanger to Pfizer's Board of Directors is effective February 1, 2009.

Where can I find more information about this announcement?

The press release dated January 14, 2009, which contains further details about Stephen W. Sanger's election, is filed as Exhibit 99 to this 8-K report. Investors can access this exhibit through the SEC's EDGAR database or Pfizer's investor relations website.

PFE 8-K: Leadership Changes

Summary

Pfizer Inc. (PFE) filed an 8-K report on January 14, 2009, to announce a change in its Board of Directors. Effective February 1, 2009, Stephen W. Sanger has been elected to the Board. This appointment is detailed in a press release issued by Pfizer on the same date, which is included as an exhibit to this filing. While the filing itself is brief and primarily procedural, the addition of a new director to the Board can be significant for investors as it may signal strategic direction, governance enhancements, or fresh perspectives. Investors should review the press release for further context on Mr. Sanger's background and any potential implications for Pfizer's future operations and leadership.

Key Highlights

1Pfizer Inc. announced the election of Stephen W. Sanger to its Board of Directors.
2The appointment of Stephen W. Sanger is effective February 1, 2009.
3This information was disclosed via a press release issued by Pfizer on January 14, 2009.
4The press release is incorporated by reference as Exhibit 99 to the 8-K filing.
5The filing primarily relates to a change in the composition of the Board of Directors.
6This event falls under Item 5.02 of Form 8-K, concerning director and officer changes.

PFIZER INC 8-K Report, Executive Changes (Jan 14, 2009)

Summary

Key Highlights

Frequently Asked Questions